http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30993426

Outgoing Links

Predicate Object
contentType Consensus Development Conference, NIH|Guideline|Journal Article
endingPage 832
issn 0920-1211
issueIdentifier 5
pageRange 825-832
publicationName Epilepsy Research
startingPage 825
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_969ccf6fe026f2f48265f62ea5c814c6
bibliographicCitation Fertig E, Fureman BE, Bergey GK, Brodie MA, Hesdorffer DC, Hirtz D, Kossoff EH, LaFrance WC, Versavel M, French J; National Institute of Neurological Disorders and Stroke. Inclusion and exclusion criteria for epilepsy clinical trials-recommendations from the April 30, 2011 NINDS workshop. Epilepsy Res. 2014 Jul;108(5):825–32. PMID: 24702822; PMCID: PMC4028380.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c8e096c49fd2055bbf2551580d5cb17e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5e765be0b77e666f3e877bf9ab87e665
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_42807a7eb8807c27362d8aa93a8568f9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_24ca13f8f97b234e4194107fe2fc2a79
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-2242-8027
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_496d4fc83b531adf6da0c49b6aa7b287
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c5039ffe5643da296122fe03b0ee9582
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6754628d038f11cd305cc368225efa3a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9ca3169bfd42fddef281b40c741dbdfd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e13a79320d2937cfdf53b5ec62a116e1
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9530c999a8ece28dc172597b9bd8a36f
date 201407
identifier https://doi.org/10.1016/j.eplepsyres.2014.02.011
https://pubmed.ncbi.nlm.nih.gov/PMC4028380
https://pubmed.ncbi.nlm.nih.gov/24702822
isPartOf https://portal.issn.org/resource/ISSN/0920-1211
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3587
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Inclusion and exclusion criteria for epilepsy clinical trials–Recommendations from the April 30, 2011 NINDS workshop
discusses http://id.nlm.nih.gov/mesh/M0001382
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D004827Q000188
http://id.nlm.nih.gov/mesh/D018579
http://id.nlm.nih.gov/mesh/D000927Q000627
http://id.nlm.nih.gov/mesh/D002986Q000379
hasSubjectTerm http://id.nlm.nih.gov/mesh/D012640Q000503
http://id.nlm.nih.gov/mesh/D004827Q000503
http://id.nlm.nih.gov/mesh/D055825
http://id.nlm.nih.gov/mesh/D000927Q000009
http://id.nlm.nih.gov/mesh/D012640Q000188
http://id.nlm.nih.gov/mesh/D014481
http://id.nlm.nih.gov/mesh/D004351
http://id.nlm.nih.gov/mesh/D004569
http://id.nlm.nih.gov/mesh/D006801
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7617
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10602
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8638

Total number of triples: 47.